两连板海南海药：派恩加滨及氟非尼酮两款创新药后续临床试验是否成功等具有不确定性

Core Viewpoint - Hainan Haiyao (000566.SZ) announced uncertainty regarding the success of clinical trials for its innovative drugs, Paiengabin and Fluorofenidone, and their potential approval by the National Medical Products Administration [1] Group 1 - The company held an investor communication event on May 24, 2025, to discuss the clinical status and characteristics of its innovative drugs [1] - The future success of the clinical trials for Paiengabin and Fluorofenidone is uncertain, as is the likelihood of receiving market approval [1] - The company commits to timely information disclosure regarding the progress of its innovative drugs [1]